| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.43, with a high estimate of $15.00 and a low estimate of $9.00. This upward trend is evident, with the current average reflecting a 0.81% increase from the previous average price target of $12.33.
The analysis of recent analyst actions sheds light on the perception of TScan Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $15.00 | $15.00 |
| Justin Zelin | BTIG | Announces | Buy | $12.00 | - |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $15.00 | $15.00 |
| Gil Blum | Needham | Maintains | Buy | $11.00 | - |
| David Nierengarten | Wedbush | Maintains | Outperform | $10.00 | - |
| Peter Lawson | Barclays | Raises | Overweight | $9.00 | $7.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $15.00 | - |
For valuable insights into TScan Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on TScan Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, TScan Therapeutics faced challenges, resulting in a decline of approximately -91.68% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: TScan Therapeutics's net margin excels beyond industry benchmarks, reaching -5325.44%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): TScan Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -22.01%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): TScan Therapeutics's ROA excels beyond industry benchmarks, reaching -11.75%. This signifies efficient management of assets and strong financial health.
Debt Management: TScan Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.75, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TCRX
